Moxifloxacin

psilodex.org/m/moxifloxacin · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: ~12 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: moxifloxacin · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Prolongs the QT interval; risk stacks with other QT-prolonging drugs. Boxed warning for central nervous system effects: fluoroquinolones are linked to seizures and psychiatric reactions including anxiety, agitation, confusion, hallucinations and paranoia.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: ~12 h (mean 12 ± 1.3 h, oral) (FDA label, checked 2026-10-02)

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

QT-prolonging: Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Moxifloxacin Hydrochloride Tablet, Film Coated · FDA label (DailyMed) — Boxed warning; 5.4 CNS effects (seizures, psychiatric reactions); 5.6 QT prolongation

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →